To include your compound in the COVID-19 Resource Center, submit it here.

Abraxane nab-paclitaxel regulatory update

The U.K.'s NICE issued draft guidance recommending against the use of Celgene's Abraxane nab-paclitaxel for first-line treatment of metastatic pancreatic cancer in combination with gemcitabine -- an indication the European Commission

Read the full 310 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE